GEHC's Optison ultrasound agent receives FDA approval for pediatric use, improving echocardiogram clarity and advancing heart ...

The Food and Drug Administration (FDA) has approved Optison ™ (perflutren protein-type A microsphere) injectable suspension for use in pediatric patients with suboptimal echocardiograms to opacify the ...

The Wall Street veteran's technical analysis of natural gas helped members capture gains on UNG calls. His recent alert ...

Low LDL cholesterol was associated with an increased risk of bleeding in patients receiving anticoagulation for venous ...

GE HealthCare (Nasdaq: GEHC) today announced the U.S. Food and Drug Administration (FDA) has approved a pediatric indication ...

Poor communication contributed to 24% of safety incidents in 42 studies that examined its contribution along with other causes. HealthDay News — Poor communication is a major contributor to ...

A cheap, non-invasive test using cell-free DNA (cfDNA) collected during standard early pregnancy testing may be used to predict preterm birth (PTB) risk, according to a recent study published in PLOS ...

Credit: FDA. The contents or quality of the counterfeit products have yet to be determined. Products with a lot number of PAR0362 coupled with the eight digits 51746517 are considered counterfeit and ...

The sBLA for dupilumab (Dupixent) was supported by data from the phase 3 LIBERTY-CUPID clinical program in patients with uncontrolled CSU. On April 18, 2025, the FDA approved a resubmitted ...

Three ultrasound contrast agents are currently approved by the US Food and Drug Administration: Definity (Lantheus); Lumason (Bracco Imaging) and Optison (GE Healthcare). The International Contrast ...